Biotech & Pharma

Medicines Discovery Catapult Backs Two U.K. Biotech Companies Tackling Chronic Diseases

24 sec read17 views0 listens

Medicines Discovery Catapult (MDC) has invested £500,000 each in two U.K. biotech firms, Flip Therapeutics and Nascent Therapeutics, to develop innovative treatments for chronic diseases like psoriasis and Parkinson’s. This support accelerates drug discovery by providing financial backing and expert guidance, crucial for advancing new therapeutic approaches that could significantly impact patient care.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

AI & Machine LearningSep 923 sec read

Man Announces That He Has Synthesized a New Schizophrenia Treatment in His Garage, Based on a Formula Devised by ChatGPT

A biochemist named Douglas Yao has synthesized a potential schizophrenia treatment called PAC-3310 in his garage, using a formula devised by AI model ChatGPT. This development highlights the growing role of AI in drug discovery but raises significant...

Ali Nemati

Biotech & PharmaSep 822 sec read

Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease

Biotech company Moonwalk Biosciences has raised $70 million to develop RNA interference (RNAi) therapies targeting obesity and cardiometabolic diseases. This funding will advance its lead candidate, MW101, into clinical trials by late 2027 and expand...

Ali Nemati

Biotech & PharmaSep 431 sec read

Cancer Drug Reduces SIV Reservoir in Macaques, May Inform HIV Cure Strategies

Researchers at Emory University found that venetoclax, a cancer drug, reduced the SIV reservoir in macaques when administered alongside antiretroviral therapy. This discovery could inform strategies to eliminate HIV's latent viral reservoir, advancin...

Ali Nemati